Several reports indicated the miR-148a-3p ability to repress proliferation and invasion in esophageal and bladder cancer, inhibit progression of epithelial ovarian cancer through directly inhibiting the expression of c-Met, as well as predict patient drug response and inhibit breast cancer progression [47,48,49,50,51]. This evidence concerns the gene MET and breast carcinoma.